Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7952W HIGH $4.18
Volume
59.09 M
Value Traded
78.71 M
Short % Float
7.43%
+0.32%Week
+62.18%1 Month
-10.57%3 Month
+6.1%6 Month
-84.94%5 Year
-81.59%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
805.76 M
EPS (TTM)
-0.06
P/E Ratio
-
Ent. Value
1.19 B
Total Shares
239.09 M
Float Shares
234.07 M
Insiders
-
Institutions
71.64%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ESPR Catalyst Timeline
Dated clinical, regulatory and corporate events for Esperion Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Esperion Therapeutics, Inc.
882Total events
15Upcoming
255Tier-1 (high impact)
2015 to 2036Coverage
Upcoming catalysts 2
Event history 50
◆Oral Presentationbempedoic acidApprovedPresentation
Factors associated with enhanced LDL-C reductions from CLEAR Outcomes presented at EAS 2026
hypercholesterolemiasource ↗
◆Oral Presentationbempedoic acidApprovedPresentation
Bempedoic Acid In Children Aged 6-17 Years With Heterozygous Familial Hypercholesterolaemia: A Phase 2 Study presented at EAS Congress 2026
heterozygous familial hypercholesterolemiasource ↗
◆Oral PresentationPresentation
Esperion to participate in 25th Annual Needham Virtual Healthcare Conference
◆Timing GuidanceNILEMDOApprovedPresentation
Expecting meaningful private payer coverage in Q2 2026
▲Product LaunchNILEMDOApprovedPost-Market
Commercial launch of NILEMDO in Canada
reduction of LDL-Cholesterol in Canadians at risk of cardiovascular diseasesource ↗
◆Other Regulator MilestoneEnbumystApprovedEx-US Regulatory
Transaction expected to close in Q2 2026
edema associated with congestive heart failure, hepatic and renal diseasesource ↗
▲Quarterly UpdateCorporate
Expecting meaningful private payer coverage for NILEMDO in Q2 2026
▲Poster PresentationNEXLETOLApprovedPresentation
Post-hoc analysis of MACE reduction in patients with AIID presented at ACC.26
cardiovascular risk reduction in autoimmune/inflammatory diseasessource ↗
◆Poster Presentationbempedoic acidApprovedPresentation
Bempedoic Acid and Cardiovascular Outcomes in Patients with Autoimmune or Inflammatory Diseases: An Analysis of the Clear Outcomes Trial
cardiovascular outcomes in patients with autoimmune or inflammatory diseasessource ↗
◆Poster Presentationbempedoic acidApprovedPresentation
Bempedoic Acid and Incidence of Stroke Among Statin-Intolerant Patients: An Analysis of The Clear Outcomes Trial
cardiovascular risk reduction in statin-intolerant patientssource ↗
▲Oral PresentationPresentation
2026 ACC/AHA Multisociety Guideline on Management of Dyslipidemia published with Class 1 recommendations for bempedoic acid
dyslipidemiasource ↗
◆Oral PresentationPresentation
Esperion to participate in 2026 Citizens Life Sciences Conference
◆Quarterly UpdateCorporate
Q4 and full year 2025 financial results and business update webcast
◆AcquisitionEnbumystApprovedCorporate
Agreement to acquire Corstasis Therapeutics and Enbumyst (bumetanide nasal spray)
edema associated with congestive heart failure, hepatic disease, renal diseasesource ↗
▲IP Litigation RulingNEXLETOLApprovedIP / Competition
Settlement agreements with five ANDA filers, including Alkem and Dr. Reddy's, restricting generic entry until April 2040
▲Development Candidate NominationESP-2001Preclinical
Nominated ESP-2001 as preclinical development candidate for PSC
primary sclerosing cholangitis (PSC)source ↗
●IND Enabling CompleteESP-2001Preclinical
Initiated IND-enabling studies for ESP-2001
primary sclerosing cholangitis (PSC)source ↗
▲Product LaunchNILEMDOApprovedPost-Market
Commercial launch of NILEMDO in Canada
reduction of LDL-C and risk of major cardiovascular events in adults with hyperlipidemia or statin intolerancesource ↗
◆Other Regulator MilestoneNEXLIZETApprovedEx-US Regulatory
Regulatory submission for NEXLIZET under review by Health Canada; HLS responding to outstanding requirements
LDL-C reductionsource ↗
▲Milestone PaymentEnbumystApprovedCorporate
Upfront cash payment of $75 million for Corstasis acquisition
▲Partnership / LicenseCorporate
Royalty monetization of Japanese royalties with Athyrium Capital Management and HealthCare Royalty
▲Hatch Waxman LitigationNEXLETOLApprovedIP / Competition
Settlement with Alkem Laboratories resolves patent litigation for NEXLETOL and NEXLIZET
hypercholesterolemiasource ↗
▲Hatch Waxman LitigationNEXLIZETApprovedIP / Competition
Settlement with Alkem Laboratories resolves patent litigation for NEXLETOL and NEXLIZET
hypercholesterolemiasource ↗
◆Timing Guidancebempedoic acidApprovedPresentation
Anticipated U.S. dyslipidemia treatment guidelines from ACC/AHA in early 2026
dyslipidemiasource ↗
▲Timing GuidanceNEXLETOLApprovedPresentation
Expected inclusion in upcoming U.S. Dyslipidemia Guidelines
dyslipidemiasource ↗
◆Oral PresentationPresentation
Esperion presentation at Piper Sandler 37th Annual Healthcare Conference
▲Product LaunchNEXLETOLApprovedPost-Market
NEXLETOL launched in Japan by Otsuka
hypercholesterolemia and familial hypercholesterolemiasource ↗
▲Milestone PaymentNEXLETOLApprovedCorporate
Esperion to receive $90 million payment from Otsuka
▲Other Regulator MilestoneNILEMDOApprovedEx-US Regulatory
Health Canada approval of NILEMDO
reduction of LDL-Cholesterol in Canadians at risk of cardiovascular diseasesource ↗
◆Oral PresentationPresentation
Esperion to present at Jefferies Global Healthcare Conference – London
◆Oral PresentationPresentation
Oral presentation: Bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events – secondary analysis of CLEAR Outcomes
cardiovascular diseasesource ↗
◆Poster PresentationPresentation
Poster presentation: Effects of Bempedoic Acid on Venous Thromboembolism – post-hoc analysis of CLEAR Outcomes
venous thromboembolismsource ↗
▲Oral PresentationNEXLETOLApprovedPresentation
Oral presentation of post hoc analysis from CLEAR Outcomes on MACE-4 reduction with bempedoic acid alone vs placebo in patients with no background LLT
cardiovascular risk reductionsource ↗
▲Poster PresentationNEXLETOLApprovedPresentation
Poster presentation of exploratory analysis from CLEAR Outcomes on VTE risk reduction with bempedoic acid vs placebo
venous thromboembolism preventionsource ↗
▲IP Litigation RulingNEXLETOLApprovedIP / Competition
Settlement with Dr. Reddy's not to market generic NEXLETOL/NEXLIZET before April 2040
dyslipidemiasource ↗
▲Other Regulator MilestoneNEXLETOLApprovedEx-US Regulatory
Otsuka received regulatory approval and favorable preliminary pricing for NEXLETOL in Japan
dyslipidemiasource ↗
▲FDA ApprovalNILEMDOApprovedFDA Decision
Health Canada approval of NILEMDO
reduction of LDL-C and risk of major cardiovascular events in adults with hyperlipidemia or statin intolerancesource ↗
Past FDA Catalysts and PDUFA Decisions
How ESPR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-24 | bempedoic acid | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D24 / 100
Pipeline Score
$0M
Pipeline Value
$1.0B
Commercial Value
Fair Value
Valuation Signal
10
Drugs Scored
-
rNPV / MCap
Esperion Therapeutics, Inc. faces pipeline headwinds (24/100), with 10 assets in development.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Mar 2026) Revenue $418.2M x 2.4 = $1.0B
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ETC-1002 Small moleculeMarketedNCT01941836 | Hypercholesterolemia | Phase 3 | COMPLETED | 2,969 | Nov 1, 2014 |
Clinical Trial Results
Readouts, endpoints and source filings for every ESPR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| bempedoic acid | heterozygous familial hypercholesterolemia | Phase 2 | 2026-05-26 | 30% or greater reduction in LDL-C; 42% of patients in the bempedoic acid arm demonstrated a ≥30% LDL‐C reduction at 3 months; LDL-C reduction in pediatric patients (range 6-25%)Read More | Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hoffman Robert E.Director | Disposition | -85,153 | $0.00 | 07/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ESPR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.6 % (20 %) | 28.96 M | 10.57 M | 77.19% ( 4.60 M) |
ESPR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ESPR ranks across every disease it competes in
Competitive Position is a premium feature
See how ESPR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialESPR News
About Esperion Therapeutics, Inc.
Headquarters3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108
BIOPHARMAWATCH ELITE PLUS
Trade the next ESPR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime